Abstract
Background
Impairment of renal function is a serious issue that should be considered in patients undergoing treatment with molecular-targeted agents for metastatic renal cell carcinoma (mRCC).
Aims
The objective of this study was to assess the impact of molecular-targeted therapy on changes in renal function among patients with mRCC.
Patients and Methods
The study included 408 mRCC patients treated with sunitinib, sorafenib, axitinib, everolimus and/or temsirolimus. Among these, 185, 128 and 95 received molecular-targeted agents as first-line (group 1), second-line (group 2) and third-line (group 3) therapy, respectively.
Results
No significant differences between the estimated glomerular filtration rate (eGFR) at baseline and that at the end of molecular-targeted therapy were noted among the three groups of patients. In addition, there were no significant differences between eGFR prior to the introduction of molecular-targeted therapy and that at the end of therapy across agents and lines of targeted therapy, with the exception of patients treated with axitinib and everolimus in second-line and third-line therapy, respectively. In group 1, a reduction in eGFR of >10 % from baseline was independently associated with performance status, hypertension and treatment duration, while in groups 2 and 3, only treatment duration was independently related to a reduction in eGFR of >10 %.
Conclusions
It appears that renal function in patients with mRCC is not markedly impaired by molecular-targeted therapies, irrespective of the specific agents introduced; however, it may be necessary to pay special attention to deterioration in renal function when molecular-targeted therapy is continued for longer periods.
Similar content being viewed by others
References
Escudier B, Albiges L, Sonpavde G (2013) Optimal management of metastatic renal cell carcinoma: current status. Drugs 73:427–438
Figlin R, Sternberg C, Wood CG (2012) Novel agents and approaches for advanced renal cell carcinoma. J Urol 188:707–715
Alasker A, Meskawi M, Sun M et al (2013) A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev 39:388–401
Cohen RB, Oudard S (2012) Antiangiogenic therapy for advanced renal cell carcinoma: management of treatment-related toxicities. Invest New Drugs 30:2066–2079
Launay-Vacher V, Aapro M, De Castro G Jr et al (2015) Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). Ann Oncol 26:1677–1684
Kelly RJ, Billemont B, Rixe O (2009) Renal toxicity of targeted therapies. Target Oncol 4:121–133
Launay-Vacher V, Ayllon J, Janus N et al (2011) Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma. Urol Oncol 29:492–494
Motzer RJ, Bacik J, Murphy BA et al (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289–296
Levey AS, Stevens LA, Schmid CH et al (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150:604–612
Huang WC, Levey AS, Serio AM et al (2006) Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study. Lancet Oncol 7:735–740
Alasker A, Meskawi M, Sun M et al (2013) A contemporary update on rates and management of toxicities of targeted therapies for metastatic renal cell carcinoma. Cancer Treat Rev 39:388–401
Rini BI, Escudier B, Tomczak P et al (2012) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase III trial. Lancet 378:1931–1939
Motzer RJ, Escudier B, Oudard S et al (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372:449–456
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
None.
Conflict of Interest
Hideaki Miyake, Mototsugu Muramaki, Satoshi Imai, Ken-ichi Harada and Masato Fujisawa declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Miyake, H., Muramaki, M., Imai, S. et al. Changes in Renal Function of Patients with Metastatic Renal Cell Carcinoma During Treatment with Molecular-Targeted Agents. Targ Oncol 11, 329–335 (2016). https://doi.org/10.1007/s11523-015-0395-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-015-0395-4